All News

Gottrons,mechanics

Hospital Mortality in Dermatomyositis

Jack Cush, MD

A cohort study shows that hospitalized patients with dermatomyositis have higher in-hospital mortality in the presence of active rash, interstitial lung disease, and elevated neutrophil to lymphocyte ratio at admission.

Read Article
ACR, guidance, guidelines

New ACR 2025 Guidelines for Non-Renal Lupus

MedPage Today

Written by Lisa Sammaritano, MD, of the Hospital for Special Surgery in New York City, and a committee of nearly 50 other experts, the new guideline also stipulates that corticosteroids are OK for gaining symptom control in newly diagnosed patients and when flares erupt, but the duration should be kept as short as possible.

Read Article
FDG,PET,CT

PET Uptake in Large Vessel GCA – Does tocilizumab help?

Brian Jaros, MD

Giant cell arteritis (GCA) is the most common form of adult vasculitis in the United States and can be subdivided into those with cranial only symptoms, those with large vessel vasculiti/PMR, and those with mixed features.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Tacrolimus in Lupus Nephritis Management

Sheila Reyes, MD

Prof. Sandra Navarra and colleagues compared the efficacy and safety of tacrolimus and glucocorticoids vs. mycophenolate mofetil (MMF) as a continuous induction-maintenance treatment for class III/IV+V lupus nephritis.

Read Article
Cush and Kavanaugh

ACR 2025 Rheumatology Round Up

Jack Cush, MD

Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.

Read Article
acr_session2.jpeg

ACR25 Best Abstracts - Day 4

Jack Cush, MD

Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty.  Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!

Read Article
Conv3.jpg

ACR 2025 – Day 2 Report

Jack Cush, MD

Here are 3 abstracts that caught my eye on Day 2 at ACR25. Notably these have takeaway messages that should support your current practices.

Read Article
PRED-SAFE: Shared Decision-Making Tool for Chronic Prednisone Use Drs. Jiha Lee and Shivani Garg discuss abstract 1052 (“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic https://t.co/ZBH61Uzzc8
Dr. John Cush RheumNow ( View Tweet)
Tapering in SELECT GCA: Steroids are the Problem Dr. Mike Putman reports on abstract 0895 (Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial) presented at #ACR25. https://t.co/80Bl49uImB https://t.co/GjlHHjPW2u

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR25 Abstract 1526 “Guidance for #Steroid Tapering in Systemic Lupus Erythematosus” 101 international experts reached Delphi consensus on CS tapering strategies in #SLE. 🔹 Practical guidance for real-world tapering across disease activity levels and organ involvement. https://t.co/GRlUz3Y3EP

Links:

Romatolog Nurullah_Akkoc ( View Tweet)
RA: Inject the Steroids Dr. Richard Conway reports on abstract 1355, "Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year," presented at the #ACR25. https://t.co/xFQMIpi75S
Dr. John Cush RheumNow ( View Tweet)
#SLE #DORIS #remission is RARE and without #prednisone even rarer #ASIA #Pacific 5K pts over 10 yrs A call to do better 82% LLDAS, 70% remission, 31% GC-free remission (REM-0) at least once abst#595 @ACRheum @RheumNow #ACRBest https://t.co/OK6sYnqs81

Links:

Janet Pope Janetbirdope ( View Tweet)
#ACR25 Clinical Preview by Prof Coates to be applied tomorrow! GC #steroid burden & Mx Abstr#738 Survey of #GCA patients in US & EU: 3/4 were still on GC; mean 5.3mg/d Abstr#1526 International consensus of GC taper in #SLE is available & can be applied in clinic @RheumNow https://t.co/paw7NGjs4p

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What exercise best for steroid-induced osteoporosis? Does it have to be weight bearing? Turns out anything helps - get out there and don’t let perfect be the enemy of good! Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/VGH2rz3dzb

Links:

David Liew drdavidliew ( View Tweet)
IgG4 - Rare but Rx Several studies #ACR25 @ACRheum were presented Outcome measures Rx #steroids #CD19 mAb #Inebilizumab 👍+RCT reduction of flares BTKi #Rilzabrutinib #Zanubrutinib #JAKi +RCT of #tofacitinib +steroids vs pred @ACRheum @RheumNow #ACR25 1163 LB02 0239 1172 https://t.co/xC3wgaN9bk

Links:

Janet Pope Janetbirdope ( View Tweet)
In RA, “strong bones” can give false reassurance. Pts with higher baseline BMD had faster bone loss, often tied to GC use and less osteoporosis treatment. Undermanagement, not biology, may drive decline. @RheumNow #ACR25 Abstract#2244 https://t.co/N421ESAUy9

Links:

Jiha Lee JihaRheum ( View Tweet)
Infection vs steroid sparing in PMR/GCA/AAV studies with steroid-sparing Rx GiACTA (1, top right) aside, - low infection rates - the more steroid saved, the less the infection risk Infection risk in vasculitis is driven by steroid, not DMARD #ACR25 ABST2526 @RheumNow https://t.co/UprbxUQyQC

Links:

David Liew drdavidliew ( View Tweet)
#1727 360k+ postmenopausal women w osteoporosis: >1/3 untreated patients were at v high fracture risk, yet few received recommended anabolic or antiresorptive therapy. Even among treated women at very high risk, >50% were still on oral bisphosphonates @RheumNow #ACR25 https://t.co/9S66tAU68P

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#ACR25 Please find my video interview with Prof Edward Vital @edvital on their work on International Consensus of Glucocorticoid Tapering Guideline in #SLE #lupus Abstr#1526 @RheumNow https://t.co/MnQdcdASkG https://t.co/b7GMcnFU2m

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR25 Abstr#1401 Sjogren’s #SjD is definitely not a benign disease! Real world study using US database showed high disease burden within 12 mths of diagnosis (i.e. healthcare resource use). GC use was high (~50%). Better therapy is needed to improve outcomes @RheumNow https://t.co/MI3vQ5LByr

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×